A patient with triple-negative breast cancer developed acute myocardial infarction after docetaxel chemotherapy: case report and literature review - Scorecard - MDSpire
Advertisement
A patient with triple-negative breast cancer developed acute myocardial infarction after docetaxel chemotherapy: case report and literature review
Clinical Scorecard: Acute Myocardial Infarction Following Docetaxel Treatment in a Patient with Triple-Negative Breast Cancer: A Case Study and Review of Relevant Literature
At a Glance
Category
Detail
Condition
Key Mechanisms
Coronary vasospasm, endothelial dysfunction, prothrombotic effects, rare occurrence of docetaxel-induced AMI
Target Population
Care Setting
Key Highlights
First reported case of AMI induced by docetaxel in breast cancer treatment
Severe occlusions found in multiple coronary arteries
Timely PCI surgery successfully performed
Docetaxel chemotherapy regimen was discontinued due to severe adverse reaction
Analysis of 94 cases of taxane-associated AMI from FAERS database, highlighting clinical relevance
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Docetaxel monotherapy led to acute myocardial infarction despite low-risk classification; prior treatments included epirubicin and cyclophosphamide.
Clinical Best Practices
Assess cardiovascular risk prior to initiating chemotherapy
Implement close monitoring for cardiac symptoms during and after chemotherapy
Educate patients on recognizing signs of myocardial infarction
Encourage interdisciplinary collaboration for comprehensive patient management.
